header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-161027-2
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.
Fish name: s705Tg
Genotype: s705Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by s705Tg
No data available
GENE EXPRESSION
Gene expression in s705Tg
Reporter gene expression No data available
PHENOTYPE
Phenotype in s705Tg
Phenotype Conditions Figures
liver ab5-akt labeling decreased amount, abnormal chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
liver ab9-rps6 labeling decreased amount, abnormal chemical treatment: sirolimus Fig. 6 from Cox et al., 2016
liver ab5-akt labeling increased amount, abnormal chemical treatment: methionine sulfoximine Fig. 6 from Cox et al., 2016
liver ab9-rps6 labeling increased amount, abnormal chemical treatment: methionine sulfoximine Fig. 6 from Cox et al., 2016
liver glulb expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver ccn1l2 expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver amotl2b expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver ccn2a expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver glula expression increased amount, abnormal standard conditions Fig. 2 from Cox et al., 2016
liver increased mass, abnormal control Fig. 7 from Cox et al., 2016
liver size, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
liver cell population proliferation increased occurrence, abnormal control Fig. 7 from Cox et al., 2016
liver cell population proliferation occurrence, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
liver glutamate-ammonia ligase activity increased occurrence, abnormal standard conditions Fig. 4,  Fig. 7 from Cox et al., 2016
liver glutamate-ammonia ligase activity occurrence, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
liver nucleotide biosynthetic process increased occurrence, abnormal control Fig. 7 from Cox et al., 2016
liver nucleotide biosynthetic process occurrence, ameliorated chemical treatment: methionine sulfoximine Fig. 7 from Cox et al., 2016
whole organism paics expression decreased amount, abnormal control Fig. S4 from Weger et al., 2018

CITATIONS  (2)